CERS1 and acute myeloid leukemia: In acute myeloid leukemia (AML), it has been shown that FLT3-ITD (mutant Fms-like tyrosine kinase 3–internal tandem duplication) downregulates the CerS1/C18-ceramide axis, inducing resistance, whereas its molecular or pharmacological targeting reactivates CerS1/C18-ceramide generation, accompanied by mitophagy and cell death both in AML cell lines and blasts obtained from FLT3-ITD1 patients and in xenograft models in vivo [24].